Completed PHASE3 INTERVENTIONAL 1-arm NCT00457626

A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension

An Open Label Extension Study to Evaluate Safety, Tolerability, and Efficacy of 18 Weeks of Valsartan Treatment in Children 6 Months-5 Years Old With Hypertension

Sponsor: Novartis Pharmaceuticals

Conditions Hypertension

Interventions Valsartan

Updated 9 times since 2017 Last updated: Sep 1, 2021 Started: Apr 9, 2007 Primary completion: May 25, 2009 Completion: May 25, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypertension and is currently completed. Novartis Pharmaceuticals leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2021 — Oct 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Jun 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ankara, Turkey (Türkiye) , Antwerp, Belgium , Budapest, Hungary , Cape Town, South Africa , Chennai, India , Curitiba, Brazil , Edegem, Belgium , Gdansk, Poland , Gezina, South Africa , Ghent, Belgium and 26 more locations